Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...

Significant regulatory progress was made with IXCHIQ, including three additional approvals and ongoing label extension activities. The company expanded market access for IXCHIQ, launching in ...

With this extension, IXCHIQ ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU).

Ixchiq received marketing authorization in Europe for individuals 18 years and older in July 2024. The European Commission will now review the CHMP recommendation, and a decision on the label ...

This submission follows the recent positive opinion of the European Medicines Agency (EMA) on extension of IXCHIQ ® label to adolescents in the European Union (EU) 2. IXCHIQ ® is the world’s first ...